Comparison of Effects of Gliclazide, Metformin and Pioglitazone Monotherapies on Glycemic Control and Cardiovascular Risk Factors in Patients with Newly Diagnosed Uncontrolled Type 2 Diabetes Mellitus
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, cilt.122, sa.5, ss.295-302, 2014 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 122 Sayı: 5
- Basım Tarihi: 2014
- Doi Numarası: 10.1055/s-0034-1370989
- Dergi Adı: EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.295-302
- Anahtar Kelimeler: gliclazide-MR, metformin, pioglitazone, type 2 diabetes, cardiovascular risk factors, glycemic control, NECROSIS-FACTOR-ALPHA, INSULIN-RESISTANCE, MODIFIED RELEASE, ENDOTHELIAL FUNCTION, DOUBLE-BLIND, ROSIGLITAZONE, MARKERS, PLASMA, HOMOCYSTEINE, INFLAMMATION
- Karadeniz Teknik Üniversitesi Adresli: Evet
Özet
Objective: The objective of this study was to evaluate and compare the effects of gliclazidemodified release (gliclazide-MR), metformine (MET) and pioglitazone (PIO) monotherapies on glycemic control and conventional/non-conventional cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus (T2DM).